Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

New contraindications for Bonviva

The European Medicines Agency (EMEA) has issued a press release detailing a recent recommendation to add two new contraindications for ibrandonic acid 150mg tablets (Bonviva®).

The existing contraindications of hypersensitivity and hypocalcaemia will be added to as follows:

  • Abnormalities of the oesophagus which delay oesophageal emptying such as stricture or achalasia
  • Inability to stand or sit upright for at least 60 minutes

The current Summary of Product Characteristics (SPC) advises that individuals with a history of prolonged oesophageal transit time should pay particular attention to the dosing instructions.

It is unlikely that any bisphosphonate would be used or tolerated in patients with these contraindications as they would be likely to experience gastrointestinal side effects such as dysphagia, oesophagitis and oesophageal or gastric ulcers. These recommended changes will simply provide clarification and clearer information for clinicians and patients.

Action: Clinicians should be aware of these recommended changes and ensure that ibrandonic acid is not being used in patients with these contraindications.

Share 'New contraindications for Bonviva' on Email Share 'New contraindications for Bonviva' on Delicious Share 'New contraindications for Bonviva' on Digg Share 'New contraindications for Bonviva' on Facebook Share 'New contraindications for Bonviva' on Google+ Share 'New contraindications for Bonviva' on reddit Share 'New contraindications for Bonviva' on StumbleUpon Share 'New contraindications for Bonviva' on Twitter

atomic-wealth

No Comments to “New contraindications for Bonviva”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,518 spam comments.

atomic-wealth
fond-illness
summer